-
3 things to know about Tom Cycyota, AlloSource president & CEO
Tom Cycyota is the president and CEO of AlloSource. -
5 things to know about BioRestorative Therapies
BioRestorative Therapies develops stem cell treatments for chronic back pain caused by disc degeneration. -
1st patient enrolled in Cerapedics' TLIF clinical trial: 5 takeaways
Cerapedics began its investigational device exemption clinical trial for its P-15L Peptide Enhanced Bone Graft. -
Who are the 10 key players in the $226B spine biologics market?
The global spine biologics market is projected to grow at a 4.4 percent compound annual growth rate, from $226 billion in 2018 to $280 billion by 2023, according to a Market Data Forecast report. -
206 Ortho gets bio-inspired patent: 3 quick notes
Orthopedic company 206 Ortho secured a patent for a new biocompatible composite designed to repair load-bearing bone and resorb without leaving a trace. -
Emory Orthopaedics & Spine Center receives $13M to study stem cell osteoarthritis treatments: 4 notes
Atlanta-based Emory Orthopaedics & Spine Center earned a $13 million grant from The Marcus Foundation for a multicenter clinical trial to evaluate stem cell treatments for osteoarthritis. -
Bone Biologics raises $5.9M: 3 notes
Bone Biologics completed $5.9 million of financing. -
Viscogliosi Brothers to purchase Bioventus' BMP development program: 5 insights
Bioventus entered into a definitive agreement to divest its bone morphogenetic protein development program to a new Viscogliosi Brothers company. -
3 things to know about Ortho RTi
Ortho Regenerative Technologies is an orthopedic biotechnology company developing novel therapeutic tissue repair devices for sports medicine surgeries. -
23 developments in spine & orthopedic biologics research in 2018
Here are 23 study developments in spine and orthopedic biologics for 2018 so far: -
3 things to know about AlloSource
AlloSource is the world's largest processor of cellular bone allografts. -
Aziyo Biologics enters co-marketing agreement with SurGenTec for minimally invasive bone graft delivery: 3 insights
Aziyo Biologics agreed to provide its viable bone matrix product ViBone to medical device company SurGenTec for use with the GraftGun universal graft delivery system. -
Cerapedics closes $22M financing round: 3 takeaways
Cerapedics completed a $22 million financing round to accelerate commercialization of its i-FACTOR Peptide Enhanced Bone Graft for degenerative disc disease. -
17 major players in the global spine biologics market
The global spine biologics market is forecasted to grow at a 4.4 percent compound annual growth rate to exceed $2.6 billion by 2020, according to a Market Research Engine report. -
Dr. Chad Lavender performs ACL repair with bone marrow: 3 things to know
Huntington, W. Va.-based Marshall Orthopaedics surgeon Chad Lavender, MD, is now performing anterior cruciate ligament repair procedures using a patient's bone marrow. -
Stem cell therapy successfully repairs torn meniscus in case study: 4 findings
Adipose-derived autologous stem cell therapy may be used to successfully repair a meniscus injury, according to a study in the Journal of Medical Cases. -
5 new biologic device launches or releases in 2018
Here are five new biologic device launches or releases in 2018 so far: -
3 things to know about the NanoFuse Bioactive Matrix
NanoFUSE Biologics will attend the 2018 International Meeting on Advanced Spine Techniques in Los Angeles between July 11 and July 14. -
SpineMark enters strategic partnership with Regenexx to boost biologic options, patient volume: 4 key points
Global spine service company SpineMark partnered with Regenexx Corp. to refer candidates for surgery at the company's centers for excellence. -
NanoFuse Biologics adds orthobiologics executive: 3 insights
NanoFUSE Biologics appointed Archie Yamada as vice president of product business development.
Page 32 of 36